Hypothyroidism After the TAVI Procedure in Elderly Patients

Sponsor
Universitair Ziekenhuis Brussel (Other)
Overall Status
Recruiting
CT.gov ID
NCT04831957
Collaborator
(none)
20
1
1
29.2
0.7

Study Details

Study Description

Brief Summary

Aortic stenosis is highly prevalent in advancing age. The prognosis of this disease has dramatically changed with the surgical replacement of the aortic valve and the trans catheter aortic valve re-placement (TAVI). The TAVI procedure is also successful in octogenarians and frail patients. However, the evaluation before the TAVI procedure requires a high dosage of iodinated contrast agent with, consequently, an increased risk for thyroid dysfunction. The primary endpoint of this study is to assess, prospectively, the incidence and the predictive factors (underlying thyroid disease, medication, food preservative, topical antiseptics) of hypothyroidism after a TAVI procedure. The secondary endpoint is the influence of the occurrence of hypothyroidism after the TAVI procedure on the geriatric assessment.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Assesment of thyroïd function
N/A

Detailed Description

Aortic stenosis is highly prevalent in advancing age. The prevalence is 2.5% at an age of 75 years and 8.1% at an age of 85 years. The estimated mortality after onset of symptoms (dizziness, syncope, thoracic pain and dyspnea) with conventional medical treatment is 75% after 3 years follow up. The prognosis of this disease has dramatically changed with the surgical replacement of the aortic valve. However, an open surgical procedure is not always possible in high risk patients for anatomical reasons (sternotomy, radiation and chest deformation) or comorbidities defined by the Euroscore and the Society of Thoracic Surgeons' risk score (STS score).

Trans-catheter aortic valve replacement (TAVI) is becoming the standard care of patients suffering of non-operable, high risk severe and symptomatic aortic stenosis. The TAVI procedure is associated with immediate hemodynamic improvement characterized by a decreased aortic valve mean pressure gradient, an improved left ventricular end systolic volume and mass, a decreased end ventricular diastolic volume and a better ejection fraction. This hemodynamic improvement translates into better clinical outcomes. Mortality rates (2.2% and 6.7% at one month and at one year) and long term stroke rate are similar after TAVI or surgical replacement.

The TAVI procedure is also successful in octogenarian and in frail patients. Consequently, patient's frailty is a growing argument to refer the patient for a percutaneous treatment of valve disease instead of a conventional surgical approach.

The standard evaluation before the TAVI procedure comprises some radiologic studies with iodinated contrast agent (coronarography, thoracic CT scanner and the TAVI procedure itself). Furthermore, some patients require a treatment with Amiodarone® because of the occurrence of atrial fibrillation during the procedure.

A typical iodinated contrast study confers 13500 µg of free iodine and 15-60g of bound iodine (several hundred thousand times above the recommended daily intake). An excess of iodium expo-sure can lead to thyroid dysfunction:

  • Hyperthyroidism particularly in patients with underlying nodular thyroid disease (Jod-Basedow effect).

  • Hypothyroidism in patients with underlying thyroid disease or in patients who are taking medication (lithium, amiodarone) which can lead to thyroid dysfunction. The mechanism of iodinated contrast agent hypothyroidism is the failure to escape of the acute Wolf-Chaikoff effect.

Amiodarone confers 3-21 mg iodine daily and can also lead to thyroid dysfunction particularly in patients with underlying thyroid disease because of the failure to escape of the acute Wolf-Chaikoff effect. An autoimmune mechanism is also described.

Epidemiology In our recent clinical practice (geriatric day hospital UZ Brussel), an increased incidence of hypothyroidism in elderly patients after a TAVI procedure has been observed. In our knowledge, there are no data about the incidence of hypothyroidism and what could be the impact for elderly patients after a TAVI procedure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Academic trial, prospective studyAcademic trial, prospective study
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Hypothyroidism After the TAVI Procedure in Elderly Patients
Actual Study Start Date :
Jul 26, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Patient underwent TAVI procedure

- Elderly patients who will undergo a TAVI procedure coming to the geriatric day hospital

Diagnostic Test: Assesment of thyroïd function
Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample

Outcome Measures

Primary Outcome Measures

  1. to assess prospectively the incidence of hypothyroidism after a TAVI procedure. [Baseline, at 4-8-12 weeks]

    Change is value of TSH and fT4,

  2. To assess the underlying thyroid disease [At baseline]

    Presence of thyroid nodule door ultra sound

  3. To assess the influence of iodinated constrast on hypothyroidism [At 4 weeks]

    Value of presence of Iodine in urine sample

  4. To assess the influence of autoimmune disease on hypothyroidism after TAVI [Baseline]

    Anti TPO

  5. To assess the influence of presence of antibodies on hypothyroidism after TAVI [Baseline]

    Anti TG

Secondary Outcome Measures

  1. to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on dependence level [Baseline and at 1 month]

    Value of dependance through : - Katz scale (ADL: assessment of activities of daily living): It rates 6 tasks of daily liv-ing (bathing, dressing, toilet, transfer, continence and eating) on a scale from 1 to 4. A low score means absence of dependence, and a high score the maximum of de-pendence for the task

  2. to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on the cognitive function [Baseline and at 1 month]

    Value of MMSE (Mini Mental Status Examination): a 0-30 score of cognitive func-tions,<25/30 meaning cognitive function impairment

  3. to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on depression [Baseline and at 1 month]

    Value of GDS (geriatric depression scale) a 0-15 score. A score > 15 means risk for depression

  4. to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on mobility [Baseline and at 1 month]

    Value of mobility through Tinetti : a 0-28 score : a score < 26 means mobility problems Timed up and go : Impaired mobility if > 12.5s 4 meter walking speed : risico for sarcopenia if speed > 0.7m/s

  5. to assess the influence of the occurrence of hypothyroidism after the TAVI procedure on instrumental daily living [Baseline and at 1 month]

    - lawton scale (assessment of instrumentary assessment of activities of daily living) a 0-27 score; a high score means independence; a low score means dependence

Eligibility Criteria

Criteria

Ages Eligible for Study:
70 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Provision of signed and dated, written Informed Consent prior to any study specific proce-dures

  • Patient: males and females must be ≥ 70 years old

  • Patients who will undergo a TAVI procedure

Exclusion Criteria:
    • No obtained signed, dated and written Informed Consent.
  • Known thyroid dysfunction (for example: Basedow, Hashimoto,...)

  • Patients receiving any of the following: Lithium, Strumazol or a recent treatment of radio-Iode

Contacts and Locations

Locations

Site City State Country Postal Code
1 UZ brussel Brussel Belgium 1090

Sponsors and Collaborators

  • Universitair Ziekenhuis Brussel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Nathalie compté, Clinic head of geriatric unit, Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT04831957
Other Study ID Numbers:
  • UZCompte3
First Posted:
Apr 5, 2021
Last Update Posted:
Aug 12, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Nathalie compté, Clinic head of geriatric unit, Universitair Ziekenhuis Brussel
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 12, 2021